Form 4: BridgeBio Oncology CEO Reports Tax Withholding Transaction

CEO Pedro Beltran disposed of 1,047 shares of BridgeBio Oncology Therapeutics to satisfy tax obligations related to RSU vesting.

Summary

• Pedro Beltran, President and CEO of BridgeBio Oncology Therapeutics, Inc. (BBOT), executed a transaction on April 1, 2026.
• The transaction involved the withholding of 1,047 shares of common stock by the issuer.
• The shares were withheld at a price of $9.03 per share.
• The purpose of the transaction was to satisfy tax withholding obligations associated with the vesting of restricted stock units (RSUs).
• Following this transaction, the reporting person maintains beneficial ownership of 45,623 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine tax-related transaction rather than a change in strategic direction or market sentiment.

Positives

• The transaction is a routine administrative action related to tax obligations rather than a discretionary sale of stock.

Negatives

• The transaction results in a minor reduction in the CEO's direct equity stake in the company.

Risks

• None identified; this is a standard regulatory disclosure for executive compensation tax compliance.

Future Outlook

Not applicable; this is a historical disclosure of a completed transaction.

Industry Context

StockSavvy.ai notes that tax-related share withholding is a standard practice for executives in the biotechnology sector to manage tax liabilities upon the vesting of equity-based compensation.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for executive equity management in publicly traded biotech firms.

Stakeholder Impact

• Minimal impact on shareholders as the transaction is a standard tax compliance measure.

Key Dates

Keywords

BridgeBio Oncology, BBOT, Form 4, Insider Trading, Tax Withholding, Executive Compensation